Anoro Ellipta is a prescription inhalation medication used to treat patients with chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis and emphysema. It is a combination of umeclidinium and vilanterol, two bronchodilators that help to open the airways [1].
When Does Anoro Ellipta Go Off Patent?
The patent expiration dates for Anoro Ellipta are complex due to multiple patents covering different aspects of the drug and its formulation. According to DrugPatentWatch.com, the earliest anticipated generic entry for Anoro Ellipta could be in 2027, though this depends on various factors, including patent litigation and potential extensions [2]. Specific patent expiry dates can vary, and more detailed information is available on DrugPatentWatch.com [2].
What Are the Side Effects of Anoro Ellipta?
Common side effects associated with Anoro Ellipta can include runny nose, sinus irritation, sore throat, cough, and changes in blood pressure [1]. More serious side effects may involve paradoxically worsening bronchospasm, allergic reactions, eye problems like glaucoma, and urinary retention [1].
How Does Anoro Ellipta Work?
Anoro Ellipta contains two active ingredients: umeclidinium and vilanterol. Umeclidinium is a long-acting muscarinic antagonist (LAMA) that works by blocking the action of acetylcholine on airway smooth muscle, leading to bronchodilation. Vilanterol is a long-acting beta2-adrenergic agonist (LABA) that stimulates beta2-adrenergic receptors in the airway smooth muscle, causing relaxation and widening of the airways [1]. Together, they provide a dual mechanism for opening and keeping the airways open [1].
Can You Get Generic Versions of Anoro Ellipta?
As of now, there are no FDA-approved generic versions of Anoro Ellipta available. Generic versions typically become available after the patents protecting the original drug expire and regulatory approval is granted [2].
What Are the Alternatives to Anoro Ellipta for COPD?
Treatment options for COPD are varied and depend on the severity of the disease and individual patient needs. Other bronchodilators, including other LAMA/LABA combinations, and inhaled corticosteroids are commonly prescribed [3]. Some patients may also benefit from theophylline, pulmonary rehabilitation, oxygen therapy, or surgical interventions in severe cases [3].
What Is the Cost of Anoro Ellipta?
The cost of Anoro Ellipta can vary significantly depending on insurance coverage, pharmacy, and dosage. Without insurance, the retail price can be several hundred dollars for a 30-day supply. Many insurance plans offer coverage, and patient assistance programs may be available from the manufacturer to help reduce out-of-pocket costs [1].
What Clinical Trials Support Anoro Ellipta's Efficacy?
The efficacy and safety of Anoro Ellipta have been evaluated in numerous clinical trials, including the pivotal UPLIFT study and subsequent studies designed to assess its long-term effects on lung function and exacerbations in COPD patients [1]. These trials have demonstrated that Anoro Ellipta improves lung function and reduces the frequency of COPD exacerbations compared to placebo and some individual bronchodilators [1].
What Are the Risks of Using Combination Inhalers Like Anoro Ellipta?
Combination inhalers, such as Anoro Ellipta, carry risks associated with both individual components. This includes the potential for side effects like increased heart rate, tremors, and nervousness from the LABA component, and urinary retention or glaucoma-related issues from the LAMA component [1]. Overuse or improper use can also lead to adverse events [1].
How Is Anoro Ellipta Different from Symbicort or Advair?
Anoro Ellipta is a combination of a LAMA (umeclidinium) and a LABA (vilanterol). In contrast, Symbicort combines an inhaled corticosteroid (budesonide) with a LABA (formoterol), and Advair combines an inhaled corticosteroid (fluticasone propionate) with a LABA (salmeterol) [4, 5]. The primary difference lies in the inclusion of an inhaled corticosteroid in Symbicort and Advair, which is not present in Anoro Ellipta. This distinction means Anoro Ellipta primarily focuses on bronchodilation, while Symbicort and Advair offer both bronchodilation and anti-inflammatory effects [4, 5].
Sources
1. Anoro Ellipta - FDA Label Information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/204034s013lbl.pdf
2. DrugPatentWatch.com. (n.d.). Anoro Ellipta Patent Information. Retrieved from https://drugpatentwatch.com/
3. Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD). (2023). GOLD Report 2023. Retrieved from https://goldcopd.org/
4. Symbicort - FDA Label Information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021163s032lbl.pdf
5. Advair - FDA Label Information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021141s056lbl.pdf